Durvalumab Is Associated with Prolonged Progression-Free Survival, While Concomitant Chemoradiotherapy May Improve Both Locoregional and Local Control in Elderly Patients with Unresectable NSCLC Stage III: Subanalysis of the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)

Introduction: The incidence of NSCLC increases with age, with a median of approximately 70 years at diagnosis. Historically, treatment strategies for locally advanced cancers have been developed predominantly in younger populations, often excluding elderly patients who may present with multiple como...

Disgrifiad llawn

Manylion Llyfryddiaeth

Prif Awduron:	Franz Zehentmayr, Josef Karner, Markus Stana, Elvis Ruznic, Barbara Zellinger, Marisa Klebermass, Ayurzana Purevdorj, Georg Gruber, Danijela Minasch, Martin Heilmann, Raphaela Moosbrugger, Falk Roeder, Brane Grambozov
Fformat:	Artigo
Iaith:	Inglês
Cyhoeddwyd:	MDPI AG 2025-12-01
Cyfres:	Medical Sciences
Pynciau:	radiation oncology NSCLC elderly sequential radiotherapy durvalumab
Mynediad Ar-lein:	https://www.mdpi.com/2076-3271/13/4/305
Tagiau:	Ychwanegu Tag Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!